Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
11 pending office actions • 5 art units • 10 examiners • 0 of 11 (0%) have an AI response strategy ready • 8 patents granted in the last 365 days
Praxis Precision Medicines Inc. has 10 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 5 distinct art units, indicating that the company's patent strategy covers several specialized biological or chemical domains. With 9 distinct examiners assigned to these 10 cases, the company experiences a high degree of examiner variety, as nearly every pending action is being reviewed by a different individual.
CHANDRAKUMAR, NIZAL S is the busiest examiner for this portfolio, currently overseeing 2 pending office actions. This examiner's involvement in 2 out of the 10 total actions makes them a key figure in the company's current prosecution landscape. For a portfolio of this size, having 9 distinct examiners means that the prosecution team must adapt to many different individual styles and requirements across the 5 art units.
The spread of 10 pending office actions across 5 distinct art units suggests a multi-faceted approach to Biotechnology & Pharmaceuticals. Because 9 distinct examiners are involved, the company must manage a wide range of feedback and potential rejections. With CHANDRAKUMAR, NIZAL S handling a portion of the actions, the remaining cases are split among other examiners, emphasizing the need for a versatile legal strategy that can address the specific nuances of each examiner's perspective.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §102 only | 2 (18%) |
| §112 only | 1 (9%) |
| Double-patenting only | 1 (9%) |
| Double-patenting + other | 2 (18%) |
| Multi-statute (no §101) | 4 (36%) |
| No statute on record | 1 (9%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHANDRAKUMAR, NIZAL S | 2 | 72.7% | +18.3% |
| SASAN, ARADHANA | 1 | 64.5% | +26.2% |
| JACKSON-TONGUE, LAKIA J | 1 | 69.0% | +20.8% |
| JACKSON, SHAWQUIA | 1 | 78.0% | -3.3% |
| VALENROD, YEVGENY | 1 | 72.6% | +25.1% |
| WHITE, DAWANNA SHAR-DAY | 1 | 62.5% | +23.3% |
| RICCI, CRAIG D | 1 | 53.5% | +52.7% |
| LEE, CHIHYI NMN | 1 | 33.7% | +60.8% |
| JARRELL, NOBLE E | 1 | 81.1% | +9.7% |
| HUTTER, GILLIAN A | 1 | 54.5% | +46.2% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18556958 | KCNT1 INHIBITORS AND METHODS OF USE | JARRELL, NOBLE E | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18546800 | HEMI-CITRATE SALTS OF GABA-A POSITIVE ALLOSTERIC MODULATOR AND CRYSTALLINE FORM THEREOF | CHANDRAKUMAR, NIZAL S | 22d |
| 19066412 | DYNAMIC CLAMPS AND METHODS OF USE THEREOF | JACKSON-TONGUE, LAKIA J | — |
| 18852579 | T-TYPE CALCIUM CHANNEL MODULATORS COMPRISING A PIPERAZINE OR 1,4-DIAZEPANE CORE AND METHODS OF USE THEREOF | WHITE, DAWANNA SHAR-DAY | — |
| 18852396 | T-TYPE CALCIUM CHANNEL MODULATORS COMPRISING A DIAZASPIROHEPTANE CORE AND METHODS OF USE THEREOF | RICCI, CRAIG D | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18546800 | HEMI-CITRATE SALTS OF GABA-A POSITIVE ALLOSTERIC MODULATOR AND CRYSTALLINE FORM THEREOF | CHANDRAKUMAR, NIZAL S | 22d |
| 19540291 | HIGH STRENGTH SINGLE UNIT DOSE FORMULATIONS AND METHODS OF USE THEREOF | SASAN, ARADHANA | — |
| 19066412 | DYNAMIC CLAMPS AND METHODS OF USE THEREOF | JACKSON-TONGUE, LAKIA J | — |
| 18927451 | TREATMENT OF NEUROLOGICAL DISORDERS | VALENROD, YEVGENY | — |
| 18852579 | T-TYPE CALCIUM CHANNEL MODULATORS COMPRISING A PIPERAZINE OR 1,4-DIAZEPANE CORE AND METHODS OF USE THEREOF | WHITE, DAWANNA SHAR-DAY | — |
| 18852396 | T-TYPE CALCIUM CHANNEL MODULATORS COMPRISING A DIAZASPIROHEPTANE CORE AND METHODS OF USE THEREOF | RICCI, CRAIG D | — |
| 18834466 | METHODS OF TREATMENT USING T-TYPE CALCIUM CHANNEL MODULATORS | LEE, CHIHYI NMN | — |
| 18746428 | FORMULATIONS OF T-TYPE CALCIUM CHANNEL MODULATORS AND METHODS OF USE THEREOF | CHANDRAKUMAR, NIZAL S | — |
| Art Unit | Apps |
|---|---|
| 1625 | 3 |
| 1615 | 1 |
| 1645 | 1 |
| 1628 | 1 |
| 1699 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19540291 | HIGH STRENGTH SINGLE UNIT DOSE FORMULATIONS AND METHODS OF USE THEREOF | SASAN, ARADHANA | 1615 | DP | Final Rejection | — | Pending | Feb 13, 2026 |
| 19066412 | DYNAMIC CLAMPS AND METHODS OF USE THEREOF | JACKSON-TONGUE, LAKIA J | 1645 | §102§112 | Non-Final OA | — | Pending | Feb 28, 2025 |
| 18864098 | METHODS OF USE OF T-TYPE CALCIUM CHANNEL MODULATORS | JACKSON, SHAWQUIA | — | §102 | Non-Final OA | — | Pending | Nov 08, 2024 |
| 18927451 | TREATMENT OF NEUROLOGICAL DISORDERS | VALENROD, YEVGENY | 1628 | §103DPOther | Non-Final OA | — | Pending | Oct 25, 2024 |
| 18852579 | T-TYPE CALCIUM CHANNEL MODULATORS COMPRISING A PIPERAZINE OR 1,4-DIAZEPANE CORE AND METHODS OF USE THEREOF | WHITE, DAWANNA SHAR-DAY | — | §102§103§112 | Non-Final OA | — | Pending | Sep 30, 2024 |
| 18852396 | T-TYPE CALCIUM CHANNEL MODULATORS COMPRISING A DIAZASPIROHEPTANE CORE AND METHODS OF USE THEREOF | RICCI, CRAIG D | — | §102§103 | Non-Final OA | — | Pending | Sep 27, 2024 |
| 18834466 | METHODS OF TREATMENT USING T-TYPE CALCIUM CHANNEL MODULATORS | LEE, CHIHYI NMN | — | §103§112DP | Non-Final OA | — | Pending | Jul 30, 2024 |
| 18746428 | FORMULATIONS OF T-TYPE CALCIUM CHANNEL MODULATORS AND METHODS OF USE THEREOF | CHANDRAKUMAR, NIZAL S | 1625 | — | Non-Final OA | — | Pending | Jun 18, 2024 |
| 18556958 | KCNT1 INHIBITORS AND METHODS OF USE | JARRELL, NOBLE E | 1699 | §112 | Non-Final OA | — | Pending | Oct 24, 2023 |
| 18546800 | HEMI-CITRATE SALTS OF GABA-A POSITIVE ALLOSTERIC MODULATOR AND CRYSTALLINE FORM THEREOF | CHANDRAKUMAR, NIZAL S | 1625 | §103§112Other | Non-Final OA | 22d | Pending | Aug 17, 2023 |
| 17607815 | KCNT1 INHIBITORS AND METHODS OF USE | HUTTER, GILLIAN A | 1625 | §102 | Final Rejection | — | Pending | Oct 29, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial